Future studies employing relevant animal models—such as genetically engineered mice or patient-derived xenografts of NSCLC—are necessary to validate the therapeutic potential of targeting CES3, assess treatment efficacy, and monitor possible toxicities. Here, CES3 is linked to non-small cell lung carcinoma.